Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMUNO BCG Moreau RJ for high-risk non-muscle invasive bladder cancer
2024-519288-17-00Phase 2Completed
- Sponsor
- Biofabri
- Start
- Dec 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Imuno BCG Moreau RJ in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Biofabri. Primary endpoint: Progression rate at 24 months after last transurethral resection. Started Dec 2024; status: completed.
02
Drugs
Imuno BCG Moreau RJ
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-519288-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519288-17-00.